Immunomedics (IMMU) Awarded 2 Small Business Grants from NIH
More News related to IMMU
- Immunomedics Announces First Quarter Fiscal 2010 Results and Clinical Program Developments
- Immunomedics to Present at Upcoming Conferences
- Immunomedics Receives Corporate Award From New Jersey Inventors Hall of Fame
- Immunomedics (IMMU) Awarded 2 Small Business Grants from NIH
- Immunomedics Awarded Three Grants by NIH to Develop New Agents for Imaging and Therapy of Cancer
More News related to FDA
- Icahn Outbids Penn National Gaming (PENN) On Bankrupt Fontainebleau Casino Project
- Overstock.com (OSTK) Dismisses Grant Thorton as Public Accounting Firm
- First Regional Bancorp (FRGB) Announces Adjustment in Taxes and Loan Losses
- NJ Attorney General Stuns TASER International (TASR) and OK's Electronic Control Devices
- Internap Network (INAP) to Amend Poison Pill
Immunomedics, Inc. (Nasdaq: IMMU) has been awarded 3 Small Business Innovation Research (SBIR) grants by the National Institutes of Health (NIH), totaling $2.1 million payable over a period of 2 years. One of the awards can be extended to 3 years with a potential $2.5 million additional funding, if certain goals and milestones are met.
The first award is a Phase I grant for the development of a hematopoietic tumor-targeting humanized antibody conjugated site-specifically with 4 interferon-a2b groups.
The NIH has also awarded the Company a multiyear Phase II grant for the development of F-18 labeled peptides for pretargeted positron-emission tomography, or PET, imaging of pancreatic cancer.
Another multiyear Phase II grant was awarded to support a clinical trial of combined radio- and immunotherapy of aggressive non-Hodgkin's lymphoma (NHL).
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
